InterMune, Inc. (ITMN) Company Profile - CorporateInformation.com


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

InterMune, Inc. Company Snapshot

Business Description:

InterMune, Inc. operates in the Pharmaceutical preparations sector. InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the Company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), which is a lung disease. Pirfenidone, which is a medicine approved for IPF, is marketed by InterMune in the European Union as Esbriet and is in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. In our complete report available for purchase the company is compared to: Progenics Pharmaceuticals, Inc., Dendreon Corporation and Vivus, Inc..

InterMune, Inc.

Stock Data:

Recent Stock Performance:

Current Price (2/3/2012): 16.00
(Figures in U.S. Dollars)

1 Week	8.8%	13 Weeks	6.3%

4 Weeks	-33.8%	52 Weeks	-56.7%

InterMune, Inc. Key Data:

Ticker:	ITMN	Country:	UNITED STATES

Exchanges:	NAS	Major Industry:	Drugs, Cosmetics & Health Care

		Sub Industry:	Ethical Drug Manufacturers

2010 Sales	26,991,000 (Year Ending Jan 2011).	Employees:	105

Currency:	U.S. Dollars	Market Cap:	1,048,122,128

Fiscal Yr Ends:	December	Shares Outstanding:	65,507,633

Share Type:	Common	Closely Held Shares:	28,128,815

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.